Company: HSDTW
Filing Date: 2025-09-15
Form Type: 424B5
Source: 0001104659-25-089776
Chunk: 0

Company: Solana Co
Filing Date: 2025-09-15
Form: 424B5
Chunk 0
---
TABLE OF CONTENTS

#### Filed Pursuant to Rule 424(b)(5)​

#### Registration No. 333-270433​

### PROSPECTUS SUPPLEMENT
**(To Prospectus dated May 26, 2023)**

#### Helius Medical Technologies, Inc.

#### Up to $92,800,000 of Class A Common Stock
**We entered into a Sales Agreement, dated September 15, 2025 (the “Sales Agreement”), with Clear Street LLC (“Clear Street”) and Maxim Group LLC (“Maxim,” and together with Clear Street, the “Sales Agents”), relating to shares of our Class A common stock, par value $0.001 per share (the “common stock”), offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having a maximum aggregate offering price of up to $92,800,000 from time to time through the Sales Agents.

Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “HSDT.” On September 12, 2025, the last reported sale price of our common stock on Nasdaq was $7.56 per share.

Sales of shares of our common stock, if any, made through the Sales Agents, or directly to the Sales Agents, as principals, as contemplated in this prospectus supplement and the accompanying prospectus, may be made in negotiated transactions or transactions that are deemed to be “at the market offerings” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. The Sales Agents are not required to sell any specific amount of shares of common stock, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations, on mutually agreed terms between the Sales Agents and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The compensation to the Sales Agents for sales of common stock sold pursuant to the Sales Agreement will be in an amount up to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale of the common stock on our behalf, the Sales Agents may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation of the Sales Agents may be deemed to be underwriting commissions or discounts.